PortfoliosLab logoPortfoliosLab logo
ZVRA vs. BYRN
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ZVRA vs. BYRN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Zevra Therapeutics Inc. (ZVRA) and Byrna Technologies Inc. (BYRN). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ZVRA achieves a 49.00% return, which is significantly higher than BYRN's -76.98% return. Over the past 10 years, ZVRA has underperformed BYRN with an annualized return of -14.94%, while BYRN has yielded a comparatively higher 4.88% annualized return.


ZVRA

1D
-4.23%
1M
2.93%
6M
57.24%
YTD
49.00%
1Y
6.54%
3Y*
40.34%
5Y*
0.06%
10Y*
-14.94%

BYRN

1D
-1.90%
1M
-40.08%
6M
-77.79%
YTD
-76.98%
1Y
-83.17%
3Y*
-1.63%
5Y*
-28.95%
10Y*
4.88%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ZVRA vs. BYRN - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ZVRA
Zevra Therapeutics Inc.
49.00%7.43%27.33%42.70%-47.30%-22.23%84.70%-78.71%-56.05%37.29%
BYRN
Byrna Technologies Inc.
-76.98%-41.72%350.86%-18.49%-41.27%-7.93%663.16%26.67%7.14%-30.00%

Correlation

The correlation between ZVRA and BYRN is 0.17, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.17

Correlation (3Y)
Calculated over the trailing 3-year period

0.18

Correlation (5Y)
Calculated over the trailing 5-year period

0.21

Correlation (10Y)
Calculated over the trailing 10-year period

0.11

Correlation (All Time)
Calculated using the full available price history since Apr 16, 2015

0.10

The correlation between ZVRA and BYRN shifts across timeframes, from 0.10 (all time) to 0.21 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

ZVRA:

$789.19M

BYRN:

$87.68M

EPS

ZVRA:

$2.15

BYRN:

-$0.16

PS Ratio

ZVRA:

6.31

BYRN:

0.84

PB Ratio

ZVRA:

3.91

BYRN:

1.54

Total Revenue (TTM)

ZVRA:

$122.29M

BYRN:

$108.86M

Gross Profit (TTM)

ZVRA:

$104.94M

BYRN:

$57.17M

EBITDA (TTM)

ZVRA:

$149.15M

BYRN:

-$3.55M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ZVRA vs. BYRN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ZVRA
ZVRA Risk / Return Rank: 5252
Overall Rank
ZVRA Sharpe Ratio Rank: 5353
Sharpe Ratio Rank
ZVRA Sortino Ratio Rank: 5252
Sortino Ratio Rank
ZVRA Omega Ratio Rank: 5252
Omega Ratio Rank
ZVRA Calmar Ratio Rank: 5353
Calmar Ratio Rank
ZVRA Martin Ratio Rank: 5151
Martin Ratio Rank

BYRN
BYRN Risk / Return Rank: 33
Overall Rank
BYRN Sharpe Ratio Rank: 44
Sharpe Ratio Rank
BYRN Sortino Ratio Rank: 22
Sortino Ratio Rank
BYRN Omega Ratio Rank: 22
Omega Ratio Rank
BYRN Calmar Ratio Rank: 22
Calmar Ratio Rank
BYRN Martin Ratio Rank: 44
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ZVRA vs. BYRN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Zevra Therapeutics Inc. (ZVRA) and Byrna Technologies Inc. (BYRN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ZVRABYRNDifference
Sharpe ratioReturn per unit of total volatility

+1.25

Sortino ratioReturn per unit of downside risk

+3.08

Omega ratioGain probability vs. loss probability

1.09

0.69

+0.40

Calmar ratioReturn relative to maximum drawdown

0.26

-0.99

+1.24

Martin ratioReturn relative to average drawdown

0.45

-1.65

+2.10

ZVRA vs. BYRN - Sharpe Ratio Comparison

The current ZVRA Sharpe Ratio is 0.18, which is higher than the BYRN Sharpe Ratio of -1.07. The chart below compares the historical Sharpe Ratios of ZVRA and BYRN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ZVRA vs. BYRN - Drawdown Comparison

The maximum ZVRA drawdown since its inception was -99.27%, which is greater than BYRN's maximum drawdown of -92.51%. Use the drawdown chart below to compare losses from any high point for ZVRA and BYRN.


Loading charts...

Drawdown Indicators


ZVRABYRNDifference

Max Drawdown

Largest peak-to-trough decline

-99.27%

-92.51%

-6.76%

Max Drawdown (1Y)

Largest decline over 1 year

-43.47%

-86.01%

+42.54%

Max Drawdown (3Y)

Largest decline over 3 years

-43.47%

-88.70%

+45.23%

Max Drawdown (5Y)

Largest decline over 5 years

-66.94%

-92.51%

+25.57%

Max Drawdown (10Y)

Largest decline over 10 years

-97.85%

-92.51%

-5.34%

Current Drawdown

Current decline from peak

-96.47%

-88.70%

-7.77%

Average Drawdown

Average peak-to-trough decline

-86.47%

-52.50%

-33.97%

Ulcer Index

Depth and duration of drawdowns from previous peaks

24.89%

51.63%

-26.74%

Volatility

ZVRA vs. BYRN - Volatility Comparison

The current volatility for Zevra Therapeutics Inc. (ZVRA) is 12.44%, while Byrna Technologies Inc. (BYRN) has a volatility of 46.46%. This indicates that ZVRA experiences smaller price fluctuations and is considered to be less risky than BYRN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ZVRABYRNDifference

Volatility (1M)

Calculated over the trailing 1-month period

12.44%

46.46%

-34.02%

Volatility (6M)

Calculated over the trailing 6-month period

40.65%

74.13%

-33.48%

Volatility (1Y)

Calculated over the trailing 1-year period

61.17%

82.31%

-21.14%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

60.33%

75.22%

-14.89%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

80.82%

96.16%

-15.34%

Dividends

ZVRA vs. BYRN - Dividend Comparison

Neither ZVRA nor BYRN has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ZVRA vs. BYRN - Financials Comparison

This section allows you to compare key financial metrics between Zevra Therapeutics Inc. and Byrna Technologies Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0010.00M20.00M30.00M40.00MJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026April
36.22M
16.39M
(ZVRA) Total Revenue
(BYRN) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ZVRA and BYRN have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

BYRN has higher volatility (46.46%) compared to ZVRA (12.44%). In terms of maximum drawdown, ZVRA dropped -99.27% vs BYRN's -92.51%.

ZVRA currently has the higher Sharpe Ratio (0.18 vs -1.07), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ZVRA and BYRN

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer